Luveltamab tazevibulin (luvelta)

About Sutro Biopharma

Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.

About Sutro Biopharma

Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.

Therapeutic Areas